Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 14-May-24 5:17 PM View:  | Artal International Sca Director 10% Owner | Lexicon Pharmaceuticals, Inc. (LXRX) | 10-May-24 | Option Exercise | 57,546,100 | -- | -- | 49% 117.55M to 175.1M | |
| 29-Apr-24 4:18 PM View: | Lefkowitz Robert J Md Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Apr-24 | Option Exercise | 8,032 | -- | -- | 20% 40.33K to 48.36K | |
| 29-Apr-24 4:20 PM View: | Sobecki Christopher J Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Apr-24 | Option Exercise | 8,032 | -- | -- | 5% 159.02K to 167.06K | |
| 29-Apr-24 4:17 PM View: | Barker Sam L Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Apr-24 | Option Exercise | 8,032 | -- | -- | 10% 79.62K to 87.65K | |
| 29-Apr-24 4:16 PM View: | Amouyal Philippe Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Apr-24 | Option Exercise | 8,032 | -- | -- | 3% 240.33K to 248.36K | |
| 29-Apr-24 4:17 PM View: | Debbane Raymond Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Apr-24 | Option Exercise | 8,032 | -- | -- | < 1% 6.79M to 6.8M | |
| 29-Apr-24 4:21 PM View: | Swain Judith L Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Apr-24 | Option Exercise | 8,032 | -- | -- | 20% 40.33K to 48.36K | |
| 13-Mar-24 9:22 PM View: | Artal International Sca Director 10% Owner | Lexicon Pharmaceuticals, Inc. (LXRX) | 13-Mar-24 | Grant | 1,150,920 | $108.50 | $124,875,000.00 | 100% 0 to 1.15M | |
| 29-Feb-24 4:30 PM View: | Main Alan J EVP, Innov & Chem Sciences | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Payment of Exercise | 24,408 | $2.62 | $63,949.00 | (9%) 280.13K to 255.72K | |
| 29-Feb-24 4:28 PM View: | Granowitz Craig B SVP, Chief Medical Officer | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Option Exercise | 63,706 | -- | -- | 420% 15.19K to 78.89K | |
| 29-Feb-24 10:00 PM View: | Coats Lonnel Chief Executive Officer Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Payment of Exercise | 61,371 | $2.62 | $160,792.00 | (5%) 1.16M to 1.1M | |
| 29-Feb-24 10:00 PM View: | Alexander Kristen VP, Finance and Accounting | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Option Exercise | 29,243 | -- | -- | 96% 30.35K to 59.59K | |
| 29-Feb-24 10:00 PM View: | Kassler-Taub Kenneth B. SVP, Regulatory & QA | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Option Exercise | 67,400 | -- | -- | 56% 119.63K to 187.03K | |
| 29-Feb-24 10:00 PM View: | Wade Jeffrey L President and CFO | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Payment of Exercise | 37,691 | $2.62 | $98,750.40 | (10%) 361.9K to 324.21K | |
| 29-Feb-24 10:00 PM View: | McDermott Wendy VP, Human Resources | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Payment of Exercise | 22,425 | $2.62 | $58,753.50 | (30%) 75.12K to 52.69K | |
| 29-Feb-24 4:30 PM View: | Main Alan J EVP, Innov & Chem Sciences | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Option Exercise | 67,546 | -- | -- | 32% 212.59K to 280.13K | |
| 29-Feb-24 10:00 PM View: | Coats Lonnel Chief Executive Officer Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Option Exercise | 245,080 | -- | -- | 27% 914.36K to 1.16M | |
| 29-Feb-24 10:00 PM View: | Crum Brian T SVP, General Counsel & Secr. | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Payment of Exercise | 25,604 | $2.62 | $67,082.50 | (13%) 203.1K to 177.5K | |
| 29-Feb-24 10:00 PM View: | Wade Jeffrey L President and CFO | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Option Exercise | 97,564 | -- | -- | 37% 264.34K to 361.9K | |
| 29-Feb-24 10:00 PM View: | McDermott Wendy VP, Human Resources | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Option Exercise | 46,641 | -- | -- | 164% 28.48K to 75.12K | |
| 29-Feb-24 4:28 PM View: | Granowitz Craig B SVP, Chief Medical Officer | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Payment of Exercise | 31,265 | $2.62 | $81,914.30 | (40%) 78.89K to 47.63K | |
| 29-Feb-24 10:00 PM View: | Alexander Kristen VP, Finance and Accounting | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Payment of Exercise | 11,793 | $2.62 | $30,897.70 | (20%) 59.59K to 47.8K | |
| 29-Feb-24 10:00 PM View: | Crum Brian T SVP, General Counsel & Secr. | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Option Exercise | 68,303 | -- | -- | 51% 134.8K to 203.1K | |
| 29-Feb-24 10:00 PM View: | Kassler-Taub Kenneth B. SVP, Regulatory & QA | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-24 | Payment of Exercise | 24,353 | $2.62 | $63,804.90 | (13%) 187.03K to 162.67K | |
| 17-Nov-23 4:55 PM View: | Coats Lonnel Chief Executive Officer Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 16-Nov-23 | Private Purchase | 90,000 | $1.05 | $94,797.00 | 11% 824.36K to 914.36K | |
| 14-Nov-23 10:00 PM View: | Amouyal Philippe Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 13-Nov-23 | Private Purchase | 200,000 | $1.01 | $201,520.00 | 496% 40.33K to 240.33K | |
| 13-Nov-23 5:31 PM View: | Coats Lonnel Chief Executive Officer Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 10-Nov-23 | Private Purchase | 10,000 | $1.01 | $10,100.00 | 1% 814.36K to 824.36K | |
| 12-Oct-23 4:01 PM View: | Debbane Raymond Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 12-Oct-23 | Purchase | 148,820 | $1.03 | $153,805.00 | 2% 6.64M to 6.79M | |
| 12-Oct-23 4:01 PM View: | Debbane Raymond Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 11-Oct-23 | Purchase | 342,874 | $1.08 | $370,784.00 | 5% 6.3M to 6.64M | |
| 12-Oct-23 4:01 PM View: | Debbane Raymond Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 10-Oct-23 | Private Purchase | 508,306 | $1.14 | $579,367.00 | 9% 5.79M to 6.3M | |
| 14-Sep-23 5:05 PM View: | Wade Jeffrey L President and CFO | Lexicon Pharmaceuticals, Inc. (LXRX) | 14-Sep-23 | Private Purchase | 10,000 | $1.38 | $13,800.00 | 4% 254.34K to 264.34K | |
| 07-Aug-23 4:13 PM View: | McDermott Wendy VP, Human Resources | Lexicon Pharmaceuticals, Inc. (LXRX) | 04-Aug-23 | Private Purchase | 6,000 | $1.84 | $11,040.00 | 27% 22.48K to 28.48K | |
| 29-Jun-23 4:13 PM View: | Coats Lonnel Chief Executive Officer Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 29-Jun-23 | Private Purchase | 10,000 | $2.16 | $21,600.00 | 1% 804.36K to 814.36K | |
| 26-Jun-23 4:04 PM View: | Coats Lonnel Chief Executive Officer Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 26-Jun-23 | Purchase | 10,000 | $2.18 | $21,792.00 | 1% 794.36K to 804.36K | |
| 27-Jun-23 4:22 PM View: | McDermott Wendy VP, Human Resources | Lexicon Pharmaceuticals, Inc. (LXRX) | 23-Jun-23 | Private Purchase | 10,000 | $2.43 | $24,300.00 | 80% 12.48K to 22.48K | |
| 26-Jun-23 4:04 PM View: | Coats Lonnel Chief Executive Officer Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 23-Jun-23 | Private Purchase | 10,000 | $2.49 | $24,950.00 | 1% 784.36K to 794.36K | |
| 22-Jun-23 4:01 PM View: | Coats Lonnel Chief Executive Officer Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 22-Jun-23 | Private Purchase | 40,000 | $2.31 | $92,400.00 | 5% 744.36K to 784.36K | |
| 20-Jun-23 4:10 PM View: | Wade Jeffrey L President and CFO | Lexicon Pharmaceuticals, Inc. (LXRX) | 20-Jun-23 | Private Purchase | 12,000 | $2.33 | $28,000.00 | 5% 242.34K to 254.34K | |
| 05-Jun-23 4:46 PM View: | Artal International Sca Director 10% Owner | Lexicon Pharmaceuticals, Inc. (LXRX) | 05-Jun-23 | Private Purchase | 27,775,000 | $2.60 | $72,215,104.00 | 31% 89.78M to 117.55M | |
| 22-May-23 4:02 PM View: | Barker Sam L Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 21-May-23 | Option Exercise | 9,302 | -- | -- | 13% 70.31K to 79.62K | |
| 22-May-23 4:06 PM View: | Sobecki Christopher J Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 21-May-23 | Option Exercise | 9,302 | -- | -- | 6% 149.72K to 159.02K | |
| 22-May-23 4:01 PM View: | Amouyal Philippe Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 21-May-23 | Option Exercise | 9,302 | -- | -- | 30% 31.03K to 40.33K | |
| 22-May-23 4:03 PM View: | Debbane Raymond Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 21-May-23 | Option Exercise | 9,302 | -- | -- | < 1% 5.78M to 5.79M | |
| 22-May-23 4:07 PM View: | Swain Judith L Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 21-May-23 | Option Exercise | 9,302 | -- | -- | 30% 31.03K to 40.33K | |
| 22-May-23 4:04 PM View: | Lefkowitz Robert J Md Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 21-May-23 | Option Exercise | 9,302 | -- | -- | 30% 31.03K to 40.33K | |
| 22-May-23 4:06 PM View: | Palantoni Frank Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 21-May-23 | Option Exercise | 9,302 | -- | -- | 30% 31.03K to 40.33K | |
| 22-May-23 4:05 PM View: | Nies Alan S Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 21-May-23 | Option Exercise | 9,302 | -- | -- | 29% 31.74K to 41.05K | |
| 01-Mar-23 4:46 PM View: | Coats Lonnel Chief Executive Officer Director | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-23 | Option Exercise | 209,327 | -- | -- | 36% 586.0K to 795.33K | |
| 01-Mar-23 4:50 PM View: | Granowitz Craig B SVP, Chief Medical Officer | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-23 | Payment of Exercise | 12,732 | $2.17 | $27,628.40 | (46%) 27.92K to 15.19K | |
| 01-Mar-23 4:56 PM View: | Alexander Kristen VP, Finance and Accounting | Lexicon Pharmaceuticals, Inc. (LXRX) | 28-Feb-23 | Payment of Exercise | 5,330 | $2.17 | $11,566.10 | (15%) 35.68K to 30.35K |
